Ved 12 måneder var hyppigheden af bivirkninger, i form af infektioner, henholdsvis 59, 6% (93) og 68, 5% (113) og hyppigheden af alvorlige bivirkninger var henholdsvis 1, 9% (3) og 8, 5% (14) for abataceptgruppen og infliximabgruppen.
At 12 months, the incidence of AE of infections were 59.6% (93), 68.5% (113), and the incidence of serious AE of infections were 1.9% (3) and 8.5% (14) for abatacept and infliximab groups, respectively.